Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy

Journal of Infectious Diseases

Volumn 196, Issue 11, 2007, Pages 1637-1644

  Schneider, John A ^a   Alam, Shaheen A ^b   Ackers, Marta ^d   Parekh, Bharat ^d   Hua, Yun Chen ^c   Graham, Parrie ^b   Gurwith, Marc ^e   Mayer, Kenneth ^f   Novak, Richard M ^b,c  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e VaxGen Inc   (United States)

^f BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VAX 004; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEXUAL INTERCOURSE; VIRUS TRANSMISSION; ADULT; ANALYSIS OF VARIANCE; BLOOD; GINGIVA; HIGH RISK BEHAVIOR; IMMUNOLOGY; LAVAGE; METABOLISM; MUCOSA; MULTICENTER STUDY; RISK; RISK FACTOR; SERODIAGNOSIS; TIME; TREATMENT OUTCOME; UNITED STATES; UNSAFE SEX; UTERINE CERVIX;

ADULT; AIDS VACCINES; ANALYSIS OF VARIANCE; CERVIX UTERI; CHICAGO; FEMALE; GINGIVA; HIV ANTIBODIES; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IRRIGATION; MUCOUS MEMBRANE; ODDS RATIO; RISK FACTORS; RISK-TAKING; TIME FACTORS; TREATMENT OUTCOME; UNSAFE SEX;

EID: 38449107679     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522232     Document Type: Article

References (50)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the global AIDS Epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2006.
2. Nguyen M, Pean P, Lopalco L, et al. HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006; 42:412-9.
3. Belyakov IM, Ahlers JD, Berzofsky JA. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines 2004; 3(4 Suppl):S65-73.
4. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165:5170-6.
5. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J Virol 2002; 76:11659-76.
6. Abel K, Compton L, Rourke T, et al. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 2003; 77:3099-118.
7. Stevceva L, Strober W. Mucosal HIV vaccines: where are we now? Curr HIV Res 2004; 2:1-10.
8. Buge SL, Richardson E, Alipanah S, et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997; 71:8531-41.
9. Wang B, Dang K, Agadjanyan MG, et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997; 15:821-5.
10. Ferko B, Stasakova J, Sereinig S, et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol 2001; 75:8899-908.
11. Durrani Z, McInerney TL, McLain L, et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 1998; 220:93-103.
12. Enose Y, Ui M, Miyake A, et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 2002; 298:306-16.
13. Moldoveanu Z, Vzorov AN, Huang WQ, Mestecky J, Compans RW. Induction of immune responses to SIV antigens by mucosally administered vaccines. AIDS Res Hum Retroviruses 1999; 15:1469-76.
14. Yao Q, Vuong V, Li M, Compans RW. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 2002; 20:2537-45.
15. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65:1387-94.
16. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Mucosal vaccination strategies for women. J Infect Dis 1999; 179(Suppl 3):S493-8.
17. Belec L, Ghys PD, Hocini H, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001; 184:1412-22.
18. Clerici M, Barassi C, Devito C, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731-41.
19. Devito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-20.
20. Buchacz K, Parekh BS, Padian NS, et al. HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retroviruses 2001; 17:1689-93.
21. Devito C, Hinkula J, Kaul R, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30:413-20.
22. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003; 17:147-56.
23. Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993; 342:69-73.
24. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77.
25. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
26. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
27. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-3.
28. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984; 226:1165-71.
29. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
30. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-67.
31. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-64.
32. Johansen FE, Pekna M, Norderhaug IN, et al. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J Exp Med 1999; 190:915-22.
33. Tran SD, Rudney JD, Sparks BS, Hodges JS. Persistent presence of Bacteroides forsythus as a risk factor for attachment loss in a population with low prevalence and severity of adult periodontitis. J Periodontol 2001; 72:1-10.
34. Jotwani R, Muthukuru M, Cutler CW. Increase in HIV receptors/coreceptors/ alpha-defensins in inflamed human gingiva. J Dent Res 2004; 83:371-7.
35. Xie H, Belogortseva NI, Wu J, Lai WH, Chen CH. Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. Antimicrob Agents Chemother 2006; 50:3070-4.
36. Zambon JJ, Grossi SG, Machtei EE, Ho AW, Dunford R, Genco RJ. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. J Periodontol 1996; 67(10 Suppl):1050-4.
37. Furber AS, Maheswaran R, Carroll CJ, Newell JN. Is smoking tobacco an independent risk factor for HIV infection and progression to AIDS? Sex Transm Infect 2006; 83:41-6.
38. Greenspan D, Komaroff E, Redford M, et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2000; 25:44-50.
39. Jin F, Prestage GP, Mao L, et al. Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the Health in Men Study. J Infect Dis 2006; 194:561-70.
40. Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1053-9.
41. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380-5.
42. Kozlowski PA, Williams SB, Lynch RM, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-74.
43. Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987; 40:153-245.
44. Haimovici F, Mayer KH, Anderson DJ. Quantitation of HIV-1-specific IgG, IgA, and IgM antibodies in human genital tract secretions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:185-91.
45. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-9.
46. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005; 79:6432-40.
47. Fontenot JD, Tan X, Phillips DM. Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. AIDS 1998; 12:1413-8.
48. Groot F, Geijtenbeek TB, Sanders RW, et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN - gp120 interaction. J Virol 2005; 79:3009-15.
49. Iqbal SBT, Ao Z, Maranan L, et al. Trappin-2: discovery of a novel inhibitor of HIV highly elevated in HIV-resistant sex workers [oral abstract session WEAA0504]. In: Program and abstracts of the AIDS 2006. XVI International AIDS Conference, Toronto, Ontario, 2006.
50. Cummins JE, Christensen L, Lennox JL, et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006; 22:788-95.